By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

What breast cancer drugs are available in Canada

MedSearch

Generic Name

Pertuzumab, Trastuzumab & hyaluronidase-zzxf subcutaneous

Brand Name

PHESGO (Perjeta, Herceptin & hyaluronidase-zzxf subcutaneous)
HER2+
Stage IV (metastatic)
Targeted Therapy
Hoffmann-La Roche Ltd.
Subcutaneous Injection
Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, Ontario, Prince Edward Island, Quebec, Saskatchewan, Yukon
No
Listed on Provincial Drug Formulary

PHESGO is indicated in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC), who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

PHESGO is INESSS recommended but not yet covered on the formulary.

For information about PHESGO for early-stage breast cancer, click here.

Yes - Open

OnCare Roche Patient Support Program

Health Canada Drug Monograph

FAQ's